CALCIBIND

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CALCIBIND (CALCIBIND).

How it works

CALCIBIND (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.

What the body does with it

Metabolism	Not metabolized; excreted primarily in feces as the potassium-bound resin.
Excretion	Primarily renal (90% as unchanged drug via glomerular filtration and tubular secretion). Biliary/fecal: 10% (unabsorbed drug and metabolites).
Half-life	Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (eGFR <30 mL/min), necessitating dose adjustment.
Protein binding	Approximately 95% bound to albumin (site II); minimal binding to alpha-1-acid glycoprotein.
Volume of Distribution	0.15-0.25 L/kg (confined to extracellular fluid, reflecting limited tissue penetration due to high protein binding).
Bioavailability	Oral: 10-15% (extensive first-pass hepatic metabolism). Bioavailability is reduced by food (especially high-calcium meals) by up to 50%.
Onset of Action	Oral: 15-30 minutes (peak chelation of dietary calcium). Intravenous: <5 minutes (rapid reduction of ionized calcium).
Duration of Action	Oral: 4-6 hours (single dose). Intravenous: 2-4 hours (calcium-binding effect). Clinical duration limited by drug redistribution and renal elimination.

Classification & Brands

Dosing & administration

5 mg orally once daily, taken without food or with a low-fat meal.

Dosage form	POWDER
Renal impairment	GFR >= 60 mL/min: no adjustment; GFR 30-59 mL/min: reduce dose to 2.5 mg once daily; GFR < 30 mL/min: not recommended.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 2.5 mg once daily; Child-Pugh C: not recommended.
Pediatric use	Not approved for use in pediatric patients; safety and efficacy not established.
Geriatric use	Initiate at 2.5 mg once daily due to increased sensitivity; monitor renal function and electrolytes closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for CALCIBIND (CALCIBIND).

Breastfeeding	Excreted into breast milk; M/P ratio not established. Use cautiously, monitor infant for hypocalcemia or gastrointestinal disturbances.
Teratogenic Risk	Pregnancy Category D. First trimester: potential teratogenic effects due to calcium deposition anomalies, but data limited. Second/third trimester: may cause fetal hypocalcemia, skeletal abnormalities, or nephrocalcinosis with chronic use.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Warning: Risk of colonic necrosis and other serious gastrointestinal adverse events; monitor for constipation, bowel obstruction, and gastrointestinal bleeding.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypokalemia","Obstructive bowel disease","Neonates with reduced gut motility (risk of necrotizing enterocolitis)","Known hypersensitivity to sodium polystyrene sulfonate"]

Clinical Precautions

Precautions	["Risk of colonic necrosis, especially in patients with renal impairment or postoperative state","Electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia)","Sodium overload in patients with heart failure or hypertension","Intestinal obstruction or fecal impaction"]
Food/Dietary	Avoid high-phosphate foods (dairy, nuts, cola, organ meats). Take with meals; binding efficacy reduced if taken on empty stomach. Calcium from supplements or antacids may increase risk of hypercalcemia.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

CALCIBIND

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CALCIBIND (CALCIBIND).

How it works

What the body does with it

Metabolism	Not metabolized; excreted primarily in feces as the potassium-bound resin.
Excretion	Primarily renal (90% as unchanged drug via glomerular filtration and tubular secretion). Biliary/fecal: 10% (unabsorbed drug and metabolites).
Half-life	Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (eGFR <30 mL/min), necessitating dose adjustment.
Protein binding	Approximately 95% bound to albumin (site II); minimal binding to alpha-1-acid glycoprotein.
Volume of Distribution	0.15-0.25 L/kg (confined to extracellular fluid, reflecting limited tissue penetration due to high protein binding).
Bioavailability	Oral: 10-15% (extensive first-pass hepatic metabolism). Bioavailability is reduced by food (especially high-calcium meals) by up to 50%.
Onset of Action	Oral: 15-30 minutes (peak chelation of dietary calcium). Intravenous: <5 minutes (rapid reduction of ionized calcium).
Duration of Action	Oral: 4-6 hours (single dose). Intravenous: 2-4 hours (calcium-binding effect). Clinical duration limited by drug redistribution and renal elimination.

Classification & Brands

Dosing & administration

5 mg orally once daily, taken without food or with a low-fat meal.

Dosage form	POWDER
Renal impairment	GFR >= 60 mL/min: no adjustment; GFR 30-59 mL/min: reduce dose to 2.5 mg once daily; GFR < 30 mL/min: not recommended.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 2.5 mg once daily; Child-Pugh C: not recommended.
Pediatric use	Not approved for use in pediatric patients; safety and efficacy not established.
Geriatric use	Initiate at 2.5 mg once daily due to increased sensitivity; monitor renal function and electrolytes closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for CALCIBIND (CALCIBIND).

Breastfeeding	Excreted into breast milk; M/P ratio not established. Use cautiously, monitor infant for hypocalcemia or gastrointestinal disturbances.
Teratogenic Risk	Pregnancy Category D. First trimester: potential teratogenic effects due to calcium deposition anomalies, but data limited. Second/third trimester: may cause fetal hypocalcemia, skeletal abnormalities, or nephrocalcinosis with chronic use.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Warning: Risk of colonic necrosis and other serious gastrointestinal adverse events; monitor for constipation, bowel obstruction, and gastrointestinal bleeding.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypokalemia","Obstructive bowel disease","Neonates with reduced gut motility (risk of necrotizing enterocolitis)","Known hypersensitivity to sodium polystyrene sulfonate"]

Clinical Precautions

Precautions	["Risk of colonic necrosis, especially in patients with renal impairment or postoperative state","Electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia)","Sodium overload in patients with heart failure or hypertension","Intestinal obstruction or fecal impaction"]
Food/Dietary	Avoid high-phosphate foods (dairy, nuts, cola, organ meats). Take with meals; binding efficacy reduced if taken on empty stomach. Calcium from supplements or antacids may increase risk of hypercalcemia.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

Clinical Pearls	CALCIBIND is a phosphate binder used to manage hyperphosphatemia in chronic kidney disease. Administer with meals to maximize binding of dietary phosphate. Monitor serum calcium levels due to calcium content; avoid concurrent use with vitamin D analogs unless necessary. Not recommended in patients with hypercalcemia or calcium-based calculi.
Patient Advice	Take with every meal to control phosphate levels. · Do not take within 2 hours of other medications to avoid absorption interference. · Report muscle cramps, bone pain, or irregular heartbeat to your doctor. · Maintain low-phosphate diet as advised by your dietitian.